Infliximab finds utility in management of pyoderma gangrenosum

Article

New Orleans - The experiences of an expanding series of patients indicate infliximab (Remicade) is a valuable therapy for the management of pyoderma gangrenosum (PG), Marketa Limova, M.D., said at the annual meeting of the American Academy of Dermatology.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.